Combination therapy with remdisivir and tocilizumab for covid-19: Lessons for futures studies

Hamideh Abbaspour Kasgari, Farhang Babamahmoodi, Ali Reza Davoudi Badabi, Ali Abbaskhani Davanloo, Parisa Moradimajd, Hamidreza Samaee

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

The outbreak of (SARS-CoV-2) originated in Wuhan, China, and pneumonia induced by this virus is named coronavirus disease 2019 (Covid-19). By March 29, 2020, 737000 people were infected and 35000 died worldwide. To date, no effective medication is recom-mended to treat SARS-CoV-2 infection, and the drugs introduced are still in the clinical trial phase. Tocilizumab and Remdisivir are possible drugs to treat and improve the symptoms of the patients. We prescribed a combination of Remdisivir and Tocilizumab to treat three critical patients with Covid-19, and presented the results in this article. After the duration of treatment with this combi-nation, one case was improved and discharged, but, unfortunately, two cases expired.
Original languageEnglish
JournalArchives of Clinical Infectious Diseases
Volume15
Issue number4
DOIs
StatePublished - 1 Jan 2020

Fingerprint Dive into the research topics of 'Combination therapy with remdisivir and tocilizumab for covid-19: Lessons for futures studies'. Together they form a unique fingerprint.

Cite this